Walgreens Boots Alliance, Inc. and Amphastar Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis

Revenue Growth: Walgreens vs. Amphastar - A Decade of Change

__timestampAmphastar Pharmaceuticals, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 201421046100076392000000
Thursday, January 1, 2015251519000103444000000
Friday, January 1, 2016255165000117351000000
Sunday, January 1, 2017240175000118214000000
Monday, January 1, 2018294666000131537000000
Tuesday, January 1, 2019322357000120074000000
Wednesday, January 1, 2020349846000121982000000
Friday, January 1, 2021437768000132509000000
Saturday, January 1, 2022498987000132703000000
Sunday, January 1, 2023644395000139081000000
Monday, January 1, 2024147658000000
Loading chart...

In pursuit of knowledge

A Tale of Two Companies: Walgreens Boots Alliance and Amphastar Pharmaceuticals

In the ever-evolving landscape of the pharmaceutical industry, Walgreens Boots Alliance and Amphastar Pharmaceuticals stand as intriguing case studies. Over the past decade, Walgreens Boots Alliance has consistently demonstrated robust growth, with revenue peaking at approximately $147 billion in 2024, marking a 93% increase from 2014. This growth trajectory underscores its dominant position in the market.

Conversely, Amphastar Pharmaceuticals, a smaller player, has shown remarkable resilience and growth, with revenues surging by over 200% from 2014 to 2023. Despite its smaller scale, Amphastar's strategic maneuvers have allowed it to carve out a significant niche.

The data reveals a compelling narrative of growth and adaptation, highlighting the contrasting strategies of a global giant and a nimble contender. Missing data for Amphastar in 2024 suggests potential challenges or strategic shifts, inviting further exploration.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025